Mecwins is pleased to announce the grant of a new U.S. Patent (US20200072829) entitled “System for Biodetection Applications”. This patent covers an innovative system for the detection and quantification of biological markers using a functionalized substrate and plasmonic nanoparticles. The technology significantly enhances the plasmonic effect, enabling highly sensitive detection in biosensing applications.
The development of this innovation was achieved in collaboration with the Bionanomechanics Laboratory of the Institute of Micro and Nanotechnology (CSIC), whose essential contributions played a fundamental role in the invention.
This milestone further solidifies Mecwins’ position as a leader in nanotechnology and biosensing, advancing the future of healthcare diagnostics.
